Edition:
United States

Auris Medical Holding AG (EARS.OQ)

EARS.OQ on NASDAQ Stock Exchange Capital Market

0.29USD
21 Sep 2018
Change (% chg)

$-0.01 (-2.13%)
Prev Close
$0.30
Open
$0.29
Day's High
$0.29
Day's Low
$0.28
Volume
53,097
Avg. Vol
176,548
52-wk High
$9.50
52-wk Low
$0.23

Latest Key Developments (Source: Significant Developments)

Auris Medical Receives Positive Scientific Advice From EMA On Development Plan And Regulatory Pathway For AM-111
Monday, 7 May 2018 07:30am EDT 

May 7 (Reuters) - Auris Medical Holding AG ::AURIS MEDICAL RECEIVES POSITIVE SCIENTIFIC ADVICE FROM EMA ON DEVELOPMENT PLAN AND REGULATORY PATHWAY FOR AM-111.AURIS MEDICAL HOLDING AG - DESIGN FOR SINGLE PIVOTAL PHASE 3 TRIAL VALIDATED BY EUROPEAN MEDICINES AGENCY.AURIS MEDICAL - INTENDS TO PROVIDE UPDATE ON PLANS FOR ADVANCING AM-111 DEVELOPMENT PROGRAM AS PART OF A GENERAL STRATEGY UPDATE ON MAY 15.  Full Article

Auris Medical Announces Early Repayment Of Part Of Its Loan Facility
Monday, 9 Apr 2018 06:45am EDT 

April 9 (Reuters) - Auris Medical Holding AG ::AURIS MEDICAL ANNOUNCES EARLY REPAYMENT OF PART OF ITS LOAN FACILITY.REPAYMENT WILL RESULT IN SIGNIFICANT REDUCTION OF CO'S INTEREST EXPENSE.  Full Article

Auris Medical Q4 Loss Per Share CHF 0.10
Thursday, 22 Mar 2018 09:05am EDT 

March 22 (Reuters) - Auris Medical Holding Ag ::AURIS MEDICAL PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE CHF 0.10.COMPANY TO REVIEW STRATEGIC OPTIONS.COMPANY TO REVIEW STRATEGIC OPTIONS.‍PREPARING FOR HEALTH AUTHORITY DISCUSSIONS OF REGULATORY PATHWAY FOR AM-111 PROGRAM​.  Full Article

Auris Medical Holding AG - Shareholders Approved Merger Between Co And Auris Medical Newco - SEC Filing
Tuesday, 13 Mar 2018 05:19pm EDT 

March 13 (Reuters) - Auris Medical Holding Ag ::AURIS MEDICAL HOLDING AG - ON MARCH 12, AT THE GENERAL MEETING, SHAREHOLDERS APPROVED MERGER BETWEEN CO AND AURIS MEDICAL NEWCO - SEC FILING.AURIS MEDICAL HOLDING AG - CO'S SHAREHOLDERS RE-ELECTED THOMAS MEYER, , AS MEMBER AND CHAIRMAN OF THE BOARD OF DIRECTORS.  Full Article

Auris Medical Holding AG Files For Resale Of Up To 7.5 Mln Common Shares Issuable Upon Exercise Of Certain Outstanding Warrants
Friday, 9 Feb 2018 04:59pm EST 

Feb 9 (Reuters) - Auris Medical Holding Ag ::AURIS MEDICAL HOLDING AG FILES FOR RESALE OF UP TO 7.5 MILLION COMMON SHARES ISSUABLE UPON EXERCISE OF CERTAIN OUTSTANDING WARRANTS - SEC FILING.  Full Article

Auris Medical Reports New Data Highlighting Superior Bioavailability Of AM-125
Wednesday, 7 Feb 2018 09:10am EST 

Feb 7 (Reuters) - Auris Medical Holding AG ::AURIS MEDICAL REPORTS NEW DATA HIGHLIGHTING SUPERIOR BIOAVAILABILITY OF AM-125 COMPARED TO ORAL BETAHISTINE.AURIS MEDICAL HOLDING - SINGLE DOSE ANIMAL STUDY DEMONSTRATES 5 TO 35 TIMES HIGHER BIOAVAILABILITY OF INTRANASAL BETAHISTINE RELATIVE TO ORAL BETAHISTINE.  Full Article

Auris Medical Announces Further Results From Healos Phase 3 Trial
Thursday, 4 Jan 2018 12:43pm EST 

Jan 4 (Reuters) - Auris Medical Holding Ag ::AURIS MEDICAL HOLDING AG SAYS ANNOUNCED FURTHER CLINICAL RESULTS FROM THE HEALOS PHASE 3 CLINICAL TRIAL, PROVIDES UPDATE ON AM-111 DEVELOPMENT PROGRAM.AURIS MEDICAL HOLDING AG SAYS AM-111 TREATED PATIENTS HAD A LOWER INCIDENCE OF NO HEARING IMPROVEMENT- SEC FILING.AURIS MEDICAL HOLDING SAYS POST-HOC ANALYSES OF TOP-LINE DATA REVEALED CLINICALLY AND STATISTICALLY SIGNIFICANT HEARING IMPROVEMENT WITH AM-111.AURIS MEDICAL HOLDING SAYS PLANS TO DISCUSS ACCUMULATED SAFETY AND EFFICACY DATA AND REGULATORY PATHWAY WITH FDA AND EMA IN Q2 OF 2018..  Full Article

Auris Medical Reports Q3 Loss Per Share CHF 0.14
Tuesday, 28 Nov 2017 06:40am EST 

Nov 28 (Reuters) - Auris Medical Holding AG ::AURIS MEDICAL REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE CHF 0.14.‍NET LOSS FOR Q3 OF 2017 WAS CHF 6.0 MILLION, OR CHF 0.14 PER SHARE​.EXPECTS THAT ITS OPERATING EXPENSES IN 2017 WILL BE LOWER THAN PREVIOUS GUIDANCE OF CHF 28 TO 32 MILLION​.‍EXPECTS THAT EXISTING CASH AND CASH EQUIVALENTS WILL ENABLE FUNDING OF OPERATIONS INTO Q2 OF 2018​.  Full Article

Auris Medical Reports Top-Line Results from Phase 3 Trial of AM-111 in Sudden Deafness
Tuesday, 28 Nov 2017 06:40am EST 

Nov 28 (Reuters) - Auris Medical Holding Ag ::AURIS MEDICAL HOLDING AG SAYS ANNOUNCED TOP-LINE RESULTS FROM THE HEALOS PHASE 3 CLINICAL TRIAL OF AM-111 IN SEVERE TO PROFOUND SUDDEN DEAFNESS.AURIS MEDICAL HOLDING AG SAYS HEALOS TRIAL DID NOT MEET PRIMARY EFFICACY ENDPOINT IN OVERALL STUDY POPULATION.AURIS MEDICAL SAYS IN HEALOS TRIAL, CLINICALLY AND STATISTICALLY SIGNIFICANT IMPROVEMENT IN SUBPOPULATION OF PATIENTS WITH PROFOUND ACUTE HEARING LOSS.AURIS MEDICAL SAYS BASED ON FINDINGS FROM HEALOS TRIAL, CONCLUDED THAT SIMILAR DESIGN OF ONGOING ASSENT TRIAL NO LONGER ADEQUATE FOR TESTING AM-111.AURIS MEDICAL HOLDING AG SAYS BASED ON FINDINGS FROM HEALOS TRIAL, ASSENT TRIAL WILL BE TERMINATED EARLY.  Full Article

Auris Medical Holding AG files for resale of up to 7.2 mln common shares
Thursday, 12 Oct 2017 04:37pm EDT 

Oct 12 (Reuters) - Auris Medical Holding Ag :Auris Medical Holding AG files for resale of up to 7.2 million common shares by selling shareholder, LPC Capital Fund Llc‍​ - SEC Filing.  Full Article

BRIEF-Auris Medical Provides Q1 Loss Per Share CHF 0.30

* AURIS MEDICAL PROVIDES BUSINESS AND STRATEGY UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS